Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs

 

A gloved hand holds a COVID-19 vaccine vial in front of a blue background

Dear President Biden and Congress: Time for US to Lead Response to the Growing COVID-19 Global Vaccine Crisis

Today we joined colleagues from CSIS, Duke University, and the COVID Collective in an open letter to the Biden Administration and US Congress with a clear message: to hasten the end of the COVID-19 global pandemic, American leadership is required to ensure universal global access to high-quality and safe vaccines, support rapid vaccine distribution and administration, and build a sustainable global network of vaccine manufacturing capacity. Vaccines offer an exit route out of the pandemic – but only if they reach a critical mass of people in need across continents, socioeconomic strata, and marginalized populations.

A container with vaccine bottles lined up next to each other

Monday Morning Vaccine Breakthrough: Terrific News for the West, but in LMICs Terms and Conditions Apply

This morning, America (and much of the world) woke up to a snippet of terrific news: Pfizer and BioNTech announced their SARS-CoV2 vaccine candidate showed 90 percent efficacy. But for policymakers in low- and middle-income countries, today’s news offers limited cause for celebration—and the Pfizer/BioNTech results may even lengthen the timeline for eventual LMIC access.

The Race for a COVID-19 Vaccine: An Overview of Current Proposals and Our Contribution in Bringing in the Missing Middle

Much rests with the successful development and introduction of an effective COVID-19 vaccine. It may be our only path towards fully reopening our economies without fear of future outbreaks and associated health and economic impacts. See here for an overview of recent vaccine initiatives.